Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Оценка качества жизни пациентов с акне тяжелой степени

https://doi.org/10.33667/2078-5631-2021-9-12-15

Полный текст:

Аннотация

Вульгарные угри являются распространенным заболеванием, поражающим до 85 % подростков. Локализация дерматоза в косметически значимых зонах, длительность течения и формирование симптомов постакне оказывают высокую психоэмоциональную нагрузку и негативно сказываются на качестве жизни. Ввиду того что акне поражает самую уязвимую и зависимую от социальной оценки возрастную группу, крайне важно не пропустить психологические отклонения, такие как тревога, депрессия и суицидальные мысли. В данном обзоре представлены виды диагностических шкал для оценки качества жизни пациентов с акне, патогенез и факторы риска образования рубцов – главного фактора, влияющего на самооценку пациентов с вульгарными угрями, а также предложены новые способы комбинированной терапии с использование кортикостероидов и изотретиноина при лечении тяжелых форм.

Об авторах

Н. В. Грязева
ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента России
Россия

 Грязева Наталья Владимировна, к. м. н., доцент кафедры
дерматовенерологии и косметологии



А. В. Тамразова
ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента России
Россия

 Тамразова Анаит Вардановна, ординатор кафедры дерматовенерологии и косметологии



Список литературы

1. Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC et al.; American Academy of Dermatology / American Academy of Dermatology Association. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007 Apr; 56 (4): 651–63. DOI: 10.1016/j.jaad.2006.08.048. Epub 2007 Feb 5. PMID:17276540.

2. Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther. 2016 Jan 19; 7: 13–25. DOI: 10.2147/AHMT.S 55832. PMID: 26955297; PMCID: PMC 4769025.

3. Makrantonaki E, Ganceviciene R, Zouboulis C. An update on the role of the sebaceous gland in the pathogenesis of acne. Dermatoendocrinol. 2011 Jan; 3 (1): 41–9. DOI: 10.4161/derm.3.1.13900. PMID: 21519409; PMCID: PMC 3051853.

4. Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009 Oct; 18 (10): 821–32. DOI: 10.1111/j.1600–0625.2009.00890.x. Epub 2009 Jun 23. PMID: 19555434.

5. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002 Aug 1; 169 (3): 1535–41. DOI: 10.4049/jimmunol.169.3.1535. PMID: 12133981; PMCID: PMC 4636337.

6. Клинические рекомендации: Акне вульгарные. Российское общество дермато-венерологов и косметологов. 2020. 33 с.

7. Sood S, Jafferany M, Vinaya Kumar S. Depression, psychiatric comorbidities, and psychosocial implications associated with acne vulgaris. J Cosmet Dermatol. 2020 Dec; 19 (12): 3177–3182. DOI: 10.1111/jocd.13753. Epub 2020 Oct15. PMID: 33006820.

8. Sulzberger MB, Zaidens SH. Psychogenic factors in dermatologic disorders. Med Clin North Am. 1948 May; 32: 669–85. DOI: 10.1016/s0025–7125(16)35686–3. PMID: 18857202.

9. Gollnick HP, Finlay AY, Shear N; Global Alliance to Improve Outcomes in Acne. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol. 2008; 9 (5): 279–84. DOI: 10.2165/00128071–200809050–00001. PMID: 18717602.

10. Samuels DV, Rosenthal R, Lin R, Chaudhari S, Natsuaki MN. Acne vulgaris and risk of depression and anxiety: A meta-analytic review. J Am Acad Dermatol. 2020 Aug; 83 (2): 532–541. DOI: 10.1016/j.jaad.2020.02.040. Epub 2020 Feb20. PMID: 32088269.

11. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May; 19 (3): 210–6. DOI: 10.1111/j.1365–2230.1994.tb01167.x. PMID: 8033378.

12. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995 Jun; 132 (6): 942–9. DOI: 10.1111/j.1365–2133.1995.tb16953.x. PMID: 7662573.

13. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997 Nov; 133 (11): 1433–40. PMID: 9371029.

14. Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol. 1989 May; 14 (3): 194–8. DOI: 10.1111/j.1365–2230.1989.tb00930.x. PMID: 2531637.

15. Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol. 1992 Jan; 17 (1): 1–3. DOI: 10.1111/j.1365–2230.1992.tb02521.x. PMID: 1424249.

16. Girman CJ, Hartmaier S, Thiboutot D, Johnson J, Barber B, DeMuro-Mercon C, Waldstreicher J. Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Qual Life Res. 1996 Oct; 5 (5): 481–90. DOI: 10.1007/BF00540020. PMID: 8973127.

17. Tan J, Fung KY, Khan S. Condensation and validation of a 4-item index of the Acne-QoL. Qual Life Res. 2006 Sep; 15 (7): 1203–10. DOI: 10.1007/s11136–006–0063–3. Epub 2006 Sep 13. PMID: 16972158.

18. Gupta MA, Johnson AM, Gupta AK. The development of an Acne Quality of Life scale: reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris. Acta Derm Venereol. 1998 Nov; 78 (6): 451–6. DOI: 10.1080/000155598442773. PMID: 9833047.

19. Rapp SR, Feldman SR, Graham G, Fleischer AB, Brenes G, Dailey M. The Acne Quality of Life Index (Acne-QOLI): development and validation of a brief instrument. Am J Clin Dermatol. 2006; 7 (3): 185–92. DOI: 10.2165/00128071–200607030–00005. PMID: 16734506.

20. Layton AM, Seukeran D, Cunliffe WJ. Scarred for life? Dermatology. 1997; 195 Suppl 1: 15–21; discussion 38–40. DOI: 10.1159/000246015. PMID: 9310741.

21. Alexis A, Daniels SR, Johnson N, Pompilus F, Burgess SM, Harper JC. Development of a new patient-reported outcome measure for facial acne: the Acne Symptom and Impact Scale (ASIS). J Drugs Dermatol. 2014 Mar; 13 (3): 333–40. PMID:24595580.

22. McLellan C, Frey MP, Thiboutot D, Layton A, Chren MM, Tan J. Development of a Comprehensive Quality-of-Life Measure for Facial and Torso Acne. J Cutan Med Surg. 2018 May/Jun; 22 (3): 304–311. DOI: 10.1177/1203475418756379. Epub 2018 Jan 31. PMID: 29383947.

23. Marron SE, Chernyshov PV, Tomas-Aragones L. Quality-of-Life Research in Acne Vulgaris: Current Status and Future Directions. Am J Clin Dermatol. 2019 Aug; 20 (4): 527–538. DOI: 10.1007/s40257–019–00438–6. PMID: 30949881.

24. Gupta A, Sharma YK, Dash KN, Chaudhari ND, Jethani S. Quality of life in acne vulgaris: Relationship to clinical severity and demographic data. Indian J Dermatol Venereol Leprol. 2016 May-Jun; 82 (3): 292–7. DOI: 10.4103/0378–6323.173593. PMID: 27088931.

25. Tan JK, Tang J, Fung K, Gupta AK, Richard Thomas D, Sapra S, et al. Development and validation of a Scale for Acne Scar Severity (SCAR-S) of the face and trunk. J Cutan Med Surg. 2010 Jul-Aug; 14 (4): 156–60. DOI: 10.2310/7750.2010.09037. PMID: 20642983.

26. Chuah SY, Goh CL. The Impact of Post-Acne Scars on the Quality of Life Among Young Adults in Singapore. J Cutan Aesthet Surg. 2015 Jul-Sep; 8 (3): 153–8. DOI: 10.4103/0974–2077.167272. PMID:26644739; PMCID: PMC 4645145.

27. Wolfram D, Tzankov A, Pülzl P, Piza-Katzer H. Hypertrophic scars and keloids – a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg. 2009 Feb; 35 (2): 171–81. DOI: 10.1111/j.1524–4725.2008.34406.x. PMID: 19215252.

28. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol. 2005 Nov; 15 (11): 599–607. DOI: 10.1016/j.tcb.2005.09.002. Epub 2005 Oct 3. PMID: 16202600.

29. Stadelmann WK, Digenis AG, Tobin GR. Physiology and healing dynamics of chronic cutaneous wounds. Am J Surg. 1998 Aug; 176 (2A Suppl): 26S-38S. DOI: 10.1016/s0002–9610(98)00183–4. PMID: 9777970.

30. Midwood KS, Williams LV, Schwarzbauer JE. Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol. 2004 Jun; 36 (6): 1031–7. DOI: 10.1016/j.biocel.2003.12.003. PMID: 15094118.

31. Тамразова О. Б. Применение репарантов в комплексной терапии хронических дерматозов. Аллергология и иммунология в педиатрии. 2016; 4 (47): 30–37.

32. Chivot M, Pawin H, Beylot C, Chosidow O, Dreno B, Faure M et al.; GROUPE EXPERTS ACNE. Cicatrices d’acné: épidémiologie, physiopathologie, clinique, traitement [Acne scars: epidemiology, physiopathology, clinical features and treatment]. Ann Dermatol Venereol. 2006 Oct; 133 (10): 813–24. French. DOI: 10.1016/s0151–9638(06)71053–5. PMID: 17072207.33. Goodman G. Acne and acne scarring – the case for active and early intervention. Aust Fam Physician. 2006 Jul; 35 (7): 503–4. PMID: 16820822.

33. Agrawal DA, Khunger N. A Morphological Study of Acne Scarring and Its Relationship between Severity and Treatment of Active Acne. J Cutan Aesthet Surg. 2020 Jul-Sep; 13(3):210–216. doi:10.4103/JCAS.JCAS_177_19. PMID: 33208997; PMCID: PMC 7646434.

34. Holland DB, Jeremy AH, Roberts SG, Seukeran DC, Layton AM, Cunliffe WJ. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. Br J Dermatol. 2004 Jan; 150 (1): 72–81. DOI: 10.1111/j.1365–2133.2004.05749.x. PMID: 14746619.

35. Tan J, Tanghetti E, Baldwin H, Stein Gold L, Lain E. The Role of Topical Retinoids in Prevention and Treatment of Atrophic Acne Scarring: Understanding the Importance of Early Effective Treatment. J Drugs Dermatol. 2019 Mar 1; 18 (3): 255–260. PMID: 30909329.

36. Ott F, Bollag W, Geiger JM. Oral 9-cis-retinoic acid versus 13-cis-retinoic acid in acne therapy. Dermatology. 1996; 193 (2): 124–6. DOI: 10.1159/000246226. PMID: 8884148.

37. Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol. 2006 Oct; 126 (10): 2178–89. DOI: 10.1038/sj.jid.5700289. Epub 2006 Mar 30. PMID: 16575387.

38. King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol. 1982 Nov; 107 (5): 583–90. DOI: 10.1111/j.1365–2133.1982.tb00410.x. PMID: 6215056.

39. Falcon RH, Lee WL, Shalita AR, Suntharalingam K, Fikrig SM. In vitro effect of isotretinoin on monocyte chemotaxis. J Invest Dermatol. 1986 May; 86 (5): 550–2. DOI: 10.1111/1523–1747.ep12355006. PMID: 3462263.

40. Thiboutot DM, Dréno B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018 Feb; 78 (2 Suppl 1): S 1–S 23.e1. DOI: 10.1016/j.jaad.2017.09.078. Epub 2017 Nov 8. PMID:29127053.

41. Evaristo LSBF, Bagatin E. Use of oral isotretinoin to treat acne in the public system: a hospital-based retrospective cohort. Sao Paulo Med J. 2019 Oct 31; 137 (4): 363–368. DOI: 10.1590/1516–3180.2018.054405072019. PMID: 31691769.

42. Bauer LB, Ornelas JN, Elston DM, Alikhan A. Isotretinoin: controversies, facts, and recommendations. Expert Rev Clin Pharmacol. 2016 Nov; 9 (11): 1435–1442. DOI: 10.1080/17512433.2016.1213629. Epub 2016 Jul 29. PMID: 27414637.

43. Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009 May; 1 (3): 162–9. DOI: 10.4161/derm.1.3.9364. PMID: 20436884; PMCID: PMC 2835909.

44. Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol. 2013; 54 (3): 157–62. PMID: 23013115; DOI: 10.1111/j.1440–0960.2012.00947.x.

45. Cohen J, Adams S, Patten S. No association found between patients receiving isotretinoin for acne and the development of depression in a Canadian prospective cohort. Can J Clin Pharmacol. 2007 Summer; 14 (2): e227–33. Epub 2007 Jun 6. PMID: 17556790.

46. Zeynep Demircay, Sadiye Kus, Haydar Sur. Predictive factors for acne flare during isotretinoin treatment. European Journal of Dermatology. 2008; 18 (4): 452–456. DOI: 10.1684/ejd.2008.0441.

47. Cuellar-Barboza AB, Cárdenas-de la Garza JA, Martínez-Moreno A, et al. Corticosteroid therapy in patients with acne. Dermatol Rev Mex. 2018; 62 (6): 506–515.

48. Chivot M. Retinoid therapy for acne. A comparative review. Am J Clin Dermatol. 2005; 6 (1): 13–9. DOI: 10.2165/00128071–200506010–00002. PMID: 15675886


Для цитирования:


Грязева Н.В., Тамразова А.В. Оценка качества жизни пациентов с акне тяжелой степени. Медицинский алфавит. 2021;(9):11-15. https://doi.org/10.33667/2078-5631-2021-9-12-15

For citation:


Gryazeva N.V., Tamrazova A.V. Assessment of quality of life in patients with severe acne. Medical alphabet. 2021;(9):11-15. (In Russ.) https://doi.org/10.33667/2078-5631-2021-9-12-15

Просмотров: 33


ISSN 2078-5631 (Print)